Stem cell therapy is being investigated as a supportive treatment for glaucoma. It may help protect optic nerve cells, support retinal health, and complement conventional glaucoma management.
Overview
Glaucoma is a group of eye diseases that damage the optic nerve, often due to increased intraocular pressure, although it can also occur with normal eye pressure. Over time, this damage can lead to progressive vision loss and, if left untreated, permanent blindness. Stem cell therapy is being studied as a regenerative approach that may support optic nerve health, reduce inflammation, and promote tissue repair. While it is not a cure for glaucoma and does not replace medications or surgery to control eye pressure, it may serve as a complementary treatment in carefully selected patients.
Glaucoma is a chronic eye condition that progressively damages the optic nerve, which carries visual information from the eye to the brain. It is one of the leading causes of irreversible blindness worldwide. Early stages often develop without noticeable symptoms, making regular eye examinations essential for early diagnosis and treatment.
Conventional glaucoma treatment focuses on lowering intraocular pressure using eye drops, laser procedures, or surgery to slow optic nerve damage. Stem cell therapy is being investigated as a regenerative approach that aims to support the health of retinal and optic nerve cells rather than lowering eye pressure directly. It is intended to complement—not replace—established glaucoma treatments.
Stem cell therapy cannot reverse existing optic nerve damage or restore vision that has already been permanently lost. Current research is evaluating whether regenerative therapies may help preserve remaining nerve cells, support retinal health, and slow disease progression in selected patients.
Mesenchymal stromal cells (MSCs) produce growth factors, cytokines, and signaling molecules that may reduce inflammation, support healthy blood circulation, protect nerve cells, and encourage tissue repair. Researchers continue to study whether these regenerative effects may help preserve optic nerve function in glaucoma.
Individual responses vary depending on disease stage, optic nerve damage, overall eye health, and ongoing glaucoma management. Stem cell therapy should be considered a supportive treatment, with continued monitoring by an ophthalmologist remaining essential.
Eligibility is determined after a comprehensive ophthalmic examination. Eye specialists evaluate glaucoma type, disease severity, visual field testing, optic nerve imaging, current treatments, and overall health before recommending regenerative therapy.
Before treatment, patients undergo a complete eye examination that may include measurement of intraocular pressure, optic nerve imaging (OCT), visual field testing, retinal evaluation, and review of medical history and previous glaucoma treatments.
| Area | Possible Changes |
|---|---|
| Optic Nerve Health | May support the health and survival of optic nerve cells. |
| Retinal Function | May help maintain healthy retinal tissue. |
| Inflammation | May reduce inflammation affecting ocular tissues. |
| Blood Supply | May support healthy circulation within the eye. |
| Visual Function | May help preserve remaining visual function in selected patients. |
| Disease Progression | May support conventional treatment aimed at slowing disease progression. |
| Eye Health | Supports the overall health of retinal and optic nerve tissues. |
| Quality of Life | May help maintain independence and daily visual function. |
| Factor | Medical Assessment |
|---|---|
| Age | Adults diagnosed with glaucoma may be evaluated individually. |
| Diagnosis | A confirmed diagnosis of glaucoma by an ophthalmologist is required. |
| Disease Stage | Doctors assess disease severity, remaining vision, and optic nerve health before recommending treatment. |
| Overall Health | Candidates should be medically stable and suitable for regenerative therapy. |
| Current Treatment | Existing medications, laser procedures, surgeries, and ophthalmic history are reviewed during treatment planning. |
Expected Benefits